A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: Advantages of pathway-based discovery

被引:27
|
作者
Hellerstein, Marc K. [1 ,2 ,3 ]
机构
[1] Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA
[2] Univ Calif San Francisco, Dept Med, Div Endocrinol & Metab, San Francisco, CA 94110 USA
[3] KineMed Inc, Emeryville, CA 94608 USA
关键词
Drug discovery and development; Pathway-based discovery; Metabolic flux analysis; Exploiting complexity;
D O I
10.1016/j.ymben.2007.09.003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Contemporary drug discovery and development (DDD) is dominated by a molecular target-based paradigm. Molecular targets that are potentially important in disease are physically characterized; chemical entities that interact with these targets are identified by ex vivo high-throughput screening assays, and optimized lead compounds enter testing as drugs. Contrary to highly publicized claims, the ascendance of this approach has in fact resulted in the lowest rate of new drug approvals in a generation. The primary explanation for low rates of new drugs is attrition, or the failure of candidates identified by molecular target-based methods to advance successfully through the DDD process. In this essay, I advance the thesis that this failure was predictable, based on modern principles of metabolic control that have emerged and been applied most forcefully in the field of metabolic engineering. These principles, such as the robustness of flux distributions, address connectivity relationships in complex metabolic networks and make it unlikely a priori that modulating most molecular targets will have predictable, beneficial functional outcomes. These same principles also suggest, however, that unexpected therapeutic actions will be common for agents that have any effect (i.e., that complexity can be exploited therapeutically). A potential operational solution (pathway-based DDD), based on observability rather than predictability, is described, focusing on emergent properties of key metabolic pathways in vivo. Recent examples of pathway-based DDD are described. In summary, the molecular target-based DDD paradigm is built on a naive and misleading model of biologic control and is not heuristically adequate for advancing the mission of modern therapeutics. New approaches that take account of and are built on principles described by metabolic engineers are needed for the next generation of DDD. (C) 2007 Published by Elsevier Inc.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [41] Bridging the Gap between Target-Based and Cell-Based Drug Discovery with a Graph Generative Multitask Model
    Hu, Fan
    Wang, Dongqi
    Huang, Huazhen
    Hu, Yishen
    Yin, Peng
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2022, 62 (23) : 6046 - 6056
  • [42] Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases
    Li, Yi
    Chen, Jianping
    Bolinger, Andrew A.
    Chen, Haiying
    Liu, Zhiqing
    Cong, Yingzi
    Brasier, Allan R.
    Pinchuk, Irina, V
    Tian, Bing
    Zhou, Jia
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (SUPPL 2) : S38 - S62
  • [43] DAIKON: A Data Acquisition, Integration, and Knowledge Capture Web Application for Target-Based Drug Discovery
    Rath, Siddhant
    Panda, Saswati
    Sacchettini, James C.
    Berthel, Steven J.
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2023, 6 (07) : 1043 - 1051
  • [44] Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases
    Li, Yi
    Chen, Jianping
    Bolinger, Andrew A.
    Chen, Haiying
    Liu, Zhiqing
    Cong, Yingzi
    Brasier, Allan R.
    Pinchuk, Irina, V
    Tian, Bing
    Zhou, Jia
    INFLAMMATORY BOWEL DISEASES, 2021, 27 : S38 - S62
  • [45] Target-Based Drug Discovery: the Emerging Success of Frontal Affinity Chromatography Coupled to Mass Spectrometry
    Calleri, Enrica
    Temporini, Caterina
    Caccialanza, Gabriele
    Massolini, Gabriella
    CHEMMEDCHEM, 2009, 4 (06) : 905 - 916
  • [46] Applications of Biophysical Tools to Target-Based Discovery of Novel Antibacterial Leads
    Lahiri, Sushmita
    Kazmirski, Steven
    Kern, Gunther
    Sanyal, Gautam
    CURRENT DRUG TARGETS, 2012, 13 (03) : 388 - 408
  • [47] Computational and Synthetic Target-based Approaches to the Discovery of Novel Anticonvulsant Compounds
    Gantner, Melisa Edith
    Llanos, Manuel Augusto
    Garofalo, Federico Mariano
    Villalba, Maria Luisa
    Gavernet, Luciana
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (33) : 6866 - 6894
  • [48] Target-based and whole-worm screening approaches to anthelmintic discovery
    Kotze, A. C.
    VETERINARY PARASITOLOGY, 2012, 186 (1-2) : 118 - 123
  • [49] Pathway-based subnetworks enable cross-disease biomarker discovery
    Haider, Syed
    Yao, Cindy Q.
    Sabine, Vicky S.
    Grzadkowski, Michal
    Stimper, Vincent
    Starmans, Maud H. W.
    Wang, Jianxin
    Nguyen, Francis
    Moon, Nathalie C.
    Lin, Xihui
    Drake, Camilla
    Crozier, Cheryl A.
    Brookes, Cassandra L.
    van de Velde, Cornelis J. H.
    Hasenburg, Annette
    Kieback, Dirk G.
    Markopoulos, Christos J.
    Dirix, Luc Y.
    Seynaeve, Caroline
    Rea, Daniel W.
    Kasprzyk, Arek
    Lambin, Philippe
    Lio', Pietro
    Bartlett, John M. S.
    Boutros, Paul C.
    NATURE COMMUNICATIONS, 2018, 9
  • [50] Abduction Based Drug Target Discovery Using Boolean Control Network
    Biane, Celia
    Delaplace, Franck
    COMPUTATIONAL METHODS IN SYSTEMS BIOLOGY (CMSB 2017), 2017, 10545 : 57 - 73